Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ROLL_DEM_DICE, DO you think AFTM is good BUY at these levels and what is your target price on it? TIA
SUBS, right said TSOI is the REAL DEAL in OTC market. Hope investors jump into it and can become very wealthy people.
Okay Subs. I just meant to point out how undermined is today's NEWS by the market and investors. Todays NEWS in TSOI was is an underrated BOMBER
Subs , with todays PR i would not be surprised to see TSOI over 1 cent today! The WHALES have not jumped into TSOI yet!
Hi RDD, just checking out AFTM they had tie with international company for distribution of their product. What it your take on the PPS target of AFTM? TIA
ROLL_DEM_DICE, you said the great prospect that TSOI could be uplisted in NASDAQ, I think SUBS had hinted us that there may be a possibility of BUYBACK of shares that would put us above 3 dollars a share to be qualified for Nasdaq listing soon!
The shareholder letter to expect to have some major future milestones. This will send TSOI PPS to pluto!
Subs you own almost 25% float of 300 million in TSOI
SUBSLOVER! saw your genuine SLAP on the ASK. GL
Subslover knows everything about TSOI . he holds 75 million shares and has got WHALES lined up to gobble up shares of TSOI next week.
Subs, after today the peeps shall be buying TSOI over 1 cent on monday!
TSOI going to close above .0035 today and next week over 1 cent
Subs, Hope your Monster whale investor is slowly getting into TSOI. Because TSOI could POP anytime.
Subs, I agree pan am cancer in Mexico is only for rich since insurance dont cover the costs.
Subs, Just to give u an idea how HOT bio tech cancer companies on nasdaq, yesterday there was IPO priced in at 8 dollars today its over 30 dollars a share and further company is still in R&D no product yet. The company name is Monopar Therapeutics Inc.
Subs, Bring on BIG GUNS so that TSOI will shoot through the PEEPS
Subs, TSOI is nice little company with tightly knit team of scientists and Doctors that dont bull shit like other hired CEO's of BIG PHARMA. It is taking time for TSOI to make its way through the regulations surrounding FDA and RTT and conducting trials at partner location in Mexico for now and may be its US locations as well.
There seems to be some resistance from BIG pharma to what TSOI has adopted RTT pathway to bring the DRUG from BENCH to BEDSIDE TO THE TERMINALLY ILL PATIENTS with low cost and faster time period..may be TSOI's disruptive mico/nano biology using natural ingredients like GINGER/GARLIC/PEACH/BLUEBERY/CASTOR OIL/COCONUT OIL/TURMERIC/GOOSEBERRY with nanoemulsfication of DRUGS to increase absorption rates in blood stream and tissue levels with higher bioavialbility is NOVEL way to not only treat BUT REVERSE the ailment is truly commendable.
subs , TSOI is most undiscovered gem in micro biotech sector..Plenty of products already in the pipeline and deals lined up almost every week this should ERUPT anytime like an volcano
Rumor is that a BIG contract is being worked and TSOI will be off to 1 cent soon!
Well said Cents. Honestly everyone wants to see 10 cents overnight
Thanks for your honest views.
stockbuster, why is that you feel that way? Please dont get me wrong. I am asking you this specifically for the benefit so many of us. Thanks.
Well January is not that far away that the only thing I can say after reading the update from Henry.
Hopefully this article will clear any doubts on the clinical trials and manuscript to be published in Peer OncologyJournals may be in January 2020
Aug 26,2019 Therapeutic Solutions International Announces Positive Clinical Data Using NanoStilbeneâ„¢ to Stimulate Immune System in Advanced Cancer Patients
Company Submits Results of Clinical Trial for Publication in Peer Reviewed Medical Journal
In the manuscript, 12 advanced cancer patients were treated for 3 weeks with 300mg daily administration of NanoStilbeneâ„¢. Immune parameters where assessed before treatment and at completion. A substantial increase in activity of T cells and NK cells was observed as a result of treatment.
It is known that NK cells are the first line of defense against cancer, and that T cells are the cellular basis for immunological memory which stops cancer from coming back. Mechanistically, the authors believed that an increase in immune response was the result of immune suppression in cancer-associated inflammation by NanoStilbeneâ„¢ [1]. It is known that the active ingredient in NanoStilbeneâ„¢, called pterostilbene, is a potent inhibitor of inflammation.
"There are numerous cancer therapies whose efficacy is controlled by the activity of the immune system. Treatments such as radiation therapy, have now been shown to be actively amplified by a strong immune system," said Dr. James Veltmeyer MD, Chief Medical Officer of the Company, and co-author of the paper. "Furthermore, it has been demonstrated that the activity of drugs such as the multi-billion dollar a year monoclonal antibody Herceptin, are dependent on an intact NK compartment."
The Company is currently selling NanoStilbeneâ„¢ as a nutraceutical and is working with several naturopathic, allopathic, integrative, and alternative medicine doctors at identifying optimum doses and combination with other drugs.
"There is a trend in oncology towards providing patients with drugs that not only kill tumors, but also have a reduced toxicity profile. Based on my experiences, I believe NanoStilbeneâ„¢ is a very promising safe, non-toxic nutraceutical adjuvant, and I am proud to be involved in its scientific development and evaluation," said Thomas Ichim, Ph.D., Board Member of TSOI and co-author of paper.
"We are honored to have such an accomplished team of collaborators that included Dr. Santosh Kesari, Senior Author of the submitted paper, and Dr. Feng Lin a distinguished tumor immunologist. To have scientists of this caliber work with us at designing, executing, and now hopefully publishing the reviewed results of this important clinical trial, is the culmination of four years of work that began with the filing of our issued US Patent 9,682,047 and the submission of this manuscript on the 23rd of August," said Timothy Dixon, President and CEO of the Company. "Our aim is to have a world without cancer, and we believe one very important advancement towards this is the integration of immunotherapies with other interventions such as our nanoformulation of pterostilbene."
Company to use Phase I Data of its Cancer Stem Cell Immunotherapy to Allow for use in the USA under President Donald Trump's Right to Try Law
OCEANSIDE, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today completion of a Phase I clinical trial in advanced cancer patients using its StemVacs cellular immunotherapy. The clinical trial was aimed at establishing the safety of StemVacs, an immunotherapeutic cell-based drug that instructs the immune system to seek and destroy cancer stem cells. It is believed that cancer stem cells are responsible for initiating the growth of tumors.
"Immunotherapy is the greatest advancement in the area of clinical oncology. FDA approved immunotherapies include the DC based product Provenge, the T cell based products Yescarta and Kymriah, and antibody based therapies such as Opdivo and Keytruda," said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International. "To our knowledge, StemVacs is the only clinical stage immunotherapeutic that kills cancer stem cells. This, combined with the safety and signals of efficacy obtained from the current Phase I clinical trial, support us to expand the use of StemVacs under President Trump's recently passed Right to Try Law."
Lot of traders may try to sway your belief and faith in TSOI. Don't let their cheap tricks play on your mind. Let TSOI recent NEWS translate into numbers and PPS shall continue to rise with strong uptrend.
In the past uptrend used to fizzle out soon, but this time around TSOI has made sure to enter into sales agreements with partners in Mexico, CHina and USA.
I am assuming update on the ongoing clinical trials would be awesome to create the much needed intensity to the shareholders and build their confidence in TSOI
Subs, I really love the way you have educated swing traders to give your perspective on TSOI.
Thank you mini. I am checking twitter NOW and I don't mind staying up all night to hear the STEALTH BOMBER NEWS from Henry!
Timothy Dixon, President, and CEO of TSOI. "The Team Wes has assembled in areas of science, marketing, and branding is second to none. We are fortunate to work with such a well-fitted and synergistic partner. This agreement only marks the beginning of a long and beneficial relationship focused on providing preventative and treatment approaches to chronic traumatic encephalopathy."
Mini, thanks for your message. Hope to receive and see the UPDATE from Henry by Friday Morning.
Jack, I am holding TSOI for gigantic returns in year 2020. Hopefully all of us benefit in this ride to over 10 cents
Why is so much disparaging comments about the number of people being treated ...some say its 2 now its going to 3. I remember there was press release on clinical data trial I where in the test results showed data on 11 patients.
I would assume there are FDA guidelines that TSOI is following in RTT pathway to treat minimum number of patients when it received FDA approval in its Phase I for PteroStilbene .
I am surprised after reading some postings raising questions about the credibility of CEO and his team to deliver after recent PR's.
I know one has to very be very careful in OTC because one has to prepared to lose all or win all investment. I would stick to our exit goals in TSOI
I have decided to stay no matter what not sell TSOI below 10 cents.
Subslover, I could not find any reference to Chinese company Beijing Regenesis. You have said you know the CEO of the Beijing Regenesis Biotechnolgy company, I am curious to know how big they are in CHINA. thanks
I am hearing definitive agreement with Beijing Regenerics will be hitting the wires soon... may be next week or so see you all buy TSOI over 10cents
Roll, you lucky person now ride will continue to over 1 cent soon!
TSOI tree is being shaken from weak to strong hands. TSOI is not typical OTC with weak endurance levels, there is unlimited firepower that is going to propel it to 1 cents by the end of month
On comparable basis with other neutraceutical companies , TSOI market cap is 100 times less. so you get the idea now.
The kind of data shown in the clinical data trial this year may point to reversing physical stress of the body makes me believe that NFL players can avoid the COLD ICE BATH that they undergo after each game to rejuvenate their bodily stress.
WCTE may look into that aspect of physiotherapy which may increase sales of PTERO STILBENE ballistically HIGHER! We have too many irons in the fire. TSOI will be banner OTC stock of the year 2019/2020
Its interesting that target market in China for anti ageing is over 80 billion which is about the same target size for CTE/TBI in USA!
I think management team at TSOI does have to concentrate on having plan to mass produce their products in massive scale at par with FDA standards under RTT law.
Good that WCTE will take care of the setting up the necessary infrastructure and team up partnerships with hospitals/wellness centres. I would not surprised to have couple of insurance companies already ready to meet TSOI management to get to the specifics of the DRUG formulations and whole nine yards.
These are exciting times for a growing biotech company with so many drugs in pipeline and small in marketcap plenty of attention right now in the industry. Isnt that a great position to be for the small team at TSOI to actually witness their hard work translating into dollars!
Thanks Cents. I think WCTE sales agreement shall be in several millions much greater than that number that will be with the Chinese Biotech ?